Abstract: The present invention relates to a transfer device for transferring medicament from a medicament container to a syringe with a needle. The transfer device is arranged for transferring accurate dosages of insulin, growth hormone or other medicaments. The accuracy is ensured by the device comprising means for mounting a syringe to the device, the needle piercing a sealing of the device. Opposite the sealing a piston is arranged, said piston being non-releasable engaged with the piston driver during transfer of the medicament. Thereby the piston is not erroneously drawn from the piston driver, which would otherwise lead to incorrect dosing. Furthermore, the device comprises dosing means including the piston driver.

Abstract: A novel class of imidazo heterocyclic compounds, pharmaceutical compositions comprising them and use thereof in the treatment and/or prevention of diseases and disorders related to the histamine H3 receptor. More particularly, the compounds are useful for the treatment and/or prevention of diseases and disorders in which an interaction with the histamine H3 receptor is beneficial.

Abstract: The present invention relates to a process comprising hydrolysis or trans esterification of one of the two enantiomeric forms of a racemic or enantiomerically enriched ester of formula I or IV by a higher rate than the other by an enzyme to give an ester and a acid (III) or two different esters (V) and (VI) with different R groups both with increased enantiomeric purity and a esterification process of a racemic or enantiomerically enriched acid (VII) by an enzyme to give an ester and an acid both with increased enantiomeric purity.

Abstract: Described is an electronic injection device wherein an electronic circuit is designed to work in two alternative modes: an air shot mode and a dose injection mode. When working in the air shot mode a small predetermined air shot dose is pressed out from the ampule when the injection button is actuated. When working in the injection mode, a dose set by operation of the dose setting means is injected by operation of the injection button. The electronic injection device is normally working in the air shot mode but shifts to work in the dose injection mode when it receives a signal indicating that the dose setting means has been operated. The circuit returns to its air shot mode when receiving a signal indicating that the set dose has been injected. This signal can originate either from a switch indicating that the protection cap is mounted or from a switch indicating that the injection button has been pressed.

Abstract: The present invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, Ar, X, Q, A, Y and Z are as defined in the specification. These compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: The present invention relates to therapeutically active azabicyclic compounds, a method of preparing the same and to pharmaceutical or veterinary compositions comprising the compounds. The novel compounds are useful in treating a disease in the central nervous system caused by malfunctioning of the muscarinic cholinergic system.

Abstract: An injection device for injecting set doses from an ampoule (2) mounted in the device, which doses are set by operation of a dose setting button (7) by which operation elastic torsion rods (14) positioned parallel with the longitudinal axis of the device are twisted. By the dose setting a torque is transmitted from the dose setting button (7) to the rods (14) through gear transmissions comprising a toothing (11) carried by a tubular (8) part coupled to the dose setting button (7) to rotate with this button. The toothing (11) engages pinions (13) fixed to the proximal ends of the torsion rods (14), which are made from a super elastic material, which can stand a deformation larger than 2% without being permanently deformed.

Abstract: The present invention provides a new stable pharmaceutical composition containing 5-[[4-[3-methyl-4-oxo-3,4-dihydro-2-quinazolinyl]methoxy]phenylmethyl]thiazolidine-2,4-dione as active ingredient.

Abstract: Novel compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by clear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: An injection device made up from a housing, a dose setting and injection mechanism, a dose setting member and an injection button is described. The dose setting and injection mechanism is made as a preassembled unit insertable into the housing. Both the dose setting member and the injection button is thereafter connected to the preassembled dose setting and injection mechanism inside the boundaries of the housing, while being accessible for a user from outside the housing. The same preassembled dose setting and injection mechanism can fit into a large variety of different houses making production of different variants of an injection device somewhat easier.

Abstract: A medicament container for storing a liquid medicament, such as insulin, comprises a wall with at least two opposite portions made of a polymer material having a light transmission at 400 nm of at least 25%, a glass transition temperature above 50° C., and a density of 0.95 g/cm3 or more. The polymer material comprises at least 70% by weight of a copolymer material composed of aliphatic cyclic or bicyclic hydrocarbons with 5 to 7 membered ring or rings and ethylene or propylene. The container is substantially inert to the medicament and, because it is either transparent or at least includes at least two opposed transparent portions, it is possible visually to inspect the contents of the container to make sure that the medicament has not crystalized or polymerized. The walls of the container provide a good barrier against m-cresol/phenol/benzyl alcohol preservatives and water.

Abstract: The present invention discloses a regimen for the treatment of type 2 diabetes, in which the endogenous secretion of insulin is stimulated in connection with meals, by administering a short-acting, oral hypoglycemic agent. Also, the present invention discloses a method of achieving improvement in glycemic control by combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.

Abstract: Novel aminoazetidine, -pyrrolidine, and -piperidine derivatives, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.

Abstract: An injection device for injection of set does of medicine from a cartridge has a nut that is screwed up along a threaded piston rod during a dose setting operation. The nut is screwed along the piston rod by rotating a dose setting drum. An injection button is coupled to the piston rod with a gear wheel transmission. Axial movement of the injection button causes a corresponding axial movement of the piston rod until the nut engages an abutment in the housing.

Abstract: The present invention relates to a method and a system for producing an elongated drug formulation being suitable for being injected through the skin of a patient with-out the use of a needle or a cannula. The drug formulation is produced by compressing a drug granulate in cavity of a system comprising a roller and a surface, wherein the roller roles over the surface thereby comprising the granulate to the formulation.

Abstract: A method of self treating a disease, such as diabetes, includes collecting in one or more databases data representing values of parameters that related to the self treatment. The data is processed to provide a plurality of alternate choices between two or more actions that may be taken and a corresponding value for each action is calculated. A computerized system may be employed to perform the above method and the system may include a computer readable medium for executing the method.

Abstract: Certain bile acids find use in the pharmaceutical industry. In view of the wide distribution of serious diseases such as HIV, AIDS and Bovine Spongiform Encephalopathy (BSE) it is desirable to avoid—as far as practicable—to have any components of animal origin in medicaments in order to eliminate any danger of infection. The present invention relates to a method of providing bile acids from non-animal starting materials.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism and obesity.

Abstract: Described are compounds of formula I wherein at least one of the bonds in the five-membered ring is a double bond; B is any alpha or beta amino acid connected to the ring with an amide or peptide bond; or a salt thereof with a pharmaceutically acceptable acid or base. Pharmaceutical compositions containing these compounds are also described. These compounds are useful for treating type II diabetes.